Update: Outbreak of Severe Acute Respiratory SyndromeWorldwide, 2003
CDC and the World Health Organization (WHO) are continuing to investigate the multicountry outbreak of unexplained atypical pneumonia referred to as severe acute respiratory syndrome (SARS) (1) . Pending development of confirmatory laboratory testing capacity, CDC's interim suspected SARS case definition (2) is based on clinical criteria and epidemiologic linkage to other SARS cases or areas with community transmission of SARS. This case definition will be updated periodically as new information becomes available. Epidemiologic and laboratory investigations of SARS are ongoing. As of April 2, 2003, a total of 2,223 suspected and/or probable SARS cases have been reported to WHO from 16 countries, including the United States (3, 4) . The reported SARS cases include 78 deaths (case-fatality proportion: 3.5%). This report summarizes SARS cases among U.S. residents and surveillance and prevention activities in the United States.
Descriptive Epidemiology
As of April 2, CDC had received 100 reports of suspected SARS cases ( Figure) from 28 states; 81 (81%) cases occurred among adults (Table) . Of these 100 suspected cases, 94 (94%) persons had traveled within the 10 days before illness onset to the areas listed in the case definition (revised on March 29 to include all of mainland China as an area with documented or suspected community transmission), four had household contact with a person with suspected SARS, and two were healthcare workers (HCWs) who provided medical care to a patient with suspected SARS. Manifestations of SARS have been relatively less severe among patients in the United States than among those reported elsewhere. A majority of U.S. patients had normal chest radiographs, and 23 (23%) were reported to have pneumonia or respiratory distress syndrome on chest radiograph, thereby meeting the WHO case definition of a probable case (4) . As of April 2, of the 40 (40%) patients who were hospitalized for >24 hours, 13 (33%) remained hospitalized; one patient had required mechanical ventilatory support, and no deaths have been reported.
Reports on the clinical status of suspected SARS cases are being received by state health departments and CDC, and household and HCW contacts are being monitored for the possibility of secondary transmission. Since SARS investigations in the United States began, some persons believed initially to have suspected SARS have been excluded on the basis of more complete clinical histories (e.g., no documented fever or respiratory symptoms) or because of testing results that indicated other etiologies. Alternative diagnoses have included infection with influenza virus, respiratory syncytial virus, Haemophilus influenzae, Streptococcus pneumoniae, and Staphylococcus aureus. Community transmission of SARS has not been identified in the United States; transmission to HCWs has been observed in one cluster involving two HCWs, compared with numerous reports of possible transmission to HCWs in other countries (5-7).
Feb Mar 10 to limit transmission in the United States have focused on early identification of potential cases through surveillance and implementation of infection-control measures in health-care settings and the community. CDC has developed interim infection-control guidelines for use in U.S. health-care and household settings (8) . These recommendations are based on experience in the United States to date and will be revised as more information becomes available. Infection-control practitioners and clinicians providing medical care for patients with suspected SARS should consult these guidelines frequently to keep current with recommendations.
Transmission in health-care settings has been documented in several countries. Transmission to HCWs appears to have occurred primarily after close contact with symptomatic persons before recommended infection-control precautions for SARS were implemented. Because a primary strategy to reduce transmission in health-care settings is early recognition and isolation of patients who might have SARS, triage practices in hospitals and ambulatory-care settings might require reevaluation. CDC guidelines for triage of potential SARS cases are available at http://www.cdc.gov/ncidod/sars/ triage_interim_guidance.htm.
In the United States, decisions to admit persons with suspected SARS to health-care facilities should be based on clinical criteria. Patients with suspected SARS who are discharged should limit interactions outside the home and not go to work, school, out-of-home child care, or other public areas until 10 days after resolution of fever and respiratory symptoms. Additional guidance for these patients is available at http:// www.cdc.gov/ncidod/sars/ic-closecontacts.htm.
The majority of U.S. residents with SARS have recovered or stabilized clinically without specific antiviral therapy. The U.S. case-fatality proportion is lower than that reported in some other countries (3) . Possible explanations for this include differing case definitions among countries or differences in the sensitivity of surveillance, leading to identification in the United States of patients with less severe or early manifestations of infection or of a larger proportion of patients with other respiratory illnesses. Until confirmatory laboratory testing is available, the case definition will include clinical criteria more likely to identify potentially infectious persons. Various therapies, including antiviral agents (e.g., oseltamivir or ribavirin) and corticosteroids, have been administered to SARS patients, but the efficacy of these therapies has not been determined.
Health-care providers of patients whose illness is consistent with the case definition for SARS should continue diagnostic evaluation for other causes of respiratory illness and, when appropriate, empiric therapy that includes activity against organisms associated with community-acquired pneumonia of uncertain etiology, including both typical and atypical respiratory pathogens (9) . Health-care providers who report suspected SARS cases should notify their state health departments if these patients receive confirmatory testing that indicates a diagnosis other than SARS. Information on suggested diagnostic testing and evaluation for persons with possible SARS is available at http://www.cdc.gov/ncidod/sars/ diagnosis.htm. The potential for transmission of SARS during airline travel is unknown. Transmission of other infectious agents (e.g., Mycobacterium tuberculosis) during air travel has been demonstrated (10) . When an airline flight crew reports a passenger with respiratory illness, quarantine officials might board the aircraft on arrival in the United States to assess whether the passenger's symptoms match the case definition of SARS and give the passenger information about following up. If a passenger with suspected SARS is identified after passengers have disembarked, public health authorities will work with the airline to contact passengers and crew for information about the development of an illness suggestive of SARS. Although ill travelers have spread SARS rapidly across international borders, the proportion, if any, of persons who acquired SARS during international travel as a result of in-flight transmission is unknown.
Despite vigorous efforts to identify and isolate suspected cases, reducing transmission of the etiologic agents of SARS might be difficult. Understanding the epidemiology of respiratory pathogens such as those that cause SARS is challenging; approximately 40%-60% of persons with pneumonia do not have a defined etiology, even when extensive testing for known respiratory pathogens is attempted (9) . Minimizing transmission will require sustained attention to infectioncontrol interventions within health-care settings and the community. The development of laboratory testing techniques to identify infected persons rapidly will be an important step toward understanding and reducing transmission of SARS. Transmission  from an Antibody-Negative Organ  and Tissue Donor -United States,  2000-2002 In June 2002, a physician reported to the Oregon Department of Human Services (DHS) a case of acute hepatitis C in a patient who had received a patellar tendon with bone allograft from a donor approximately 6 weeks before onset of illness. At the time of the donor's death in October 2000, his serum had no detectable antibody to hepatitis C virus (anti-HCV). The ensuing investigation conducted by CDC and DHS confirmed that the donor, although anti-HCVnegative, was HCV RNA-positive and the probable source of HCV infection for at least eight organ and tissue recipients. This report summarizes the preliminary results of the investigation. Although transmission from anti-HCVnegative tissue donors probably is rare, determining the frequency of transplantations from such donors and the risk for transmitting HCV to recipients is important in evaluating whether additional prevention measures are warranted.
Hepatitis C Virus
The donor was a man in his 40s with a history of hypertension and heavy alcohol use who died of an intracranial hemorrhage. At the time of death, he had no signs or symptoms of hepatitis, and his alanine aminotransferase and aspartate aminotransferase levels were normal. Physical examination revealed no skin markings indicative of injection-drug use or evidence of liver disease. A questionnaire administered to the donor's next of kin revealed no history of injection-drug use or blood transfusion.
At the time of the donor's death, his serum tested negative for anti-HCV by a second-generation enzyme immunoassay (EIA) (Abbott HCV EIA 2.0, Abbott Laboratories, Abbott Park, Illinois) and negative for human immunodeficiency virus (HIV)-1, HIV-2, human T-lymphotropic virus (HTLV) I, HTLV II, hepatitis B virus, and syphilis. In July 2002, stored, frozen serum obtained premortem from the donor tested negative for anti-HCV with a third-generation EIA (ORTHO ® HCV Version 3.0 ELISA, Ortho-Clinical Diagnostics, Raritan, New Jersey) but positive for HCV RNA (AMPLICOR ® HCV Test, version 2.0, Roche Molecular Systems, Branchburg, New Jersey). The donor's HCV genotype was 1a, as determined from the 300-nucleotide sequence of the nonstructural coding region NS5b (1, 2) .
A case was defined as laboratory-confirmed HCV infection, with a viral genotype identical to that of the donor, in a recipient not known to have been infected before transplantation. A definite case was defined as one that occurred in a recipient who was both anti-HCV-and HCV RNA-negative before transplantation. A probable case was defined as one that occurred in a recipient for whom no serum was available before transplantation.
The organ procurement and tissue distribution agencies provided an inventory of grafts recovered from the donor and the contact information for each health-care provider or facility that had received grafts. Health-care providers were contacted to obtain clinical information and to arrange for testing of recipients. Recipients' post-transplantation and stored pretransplantation sera, when available, were tested for anti-HCV by EIA 2.0 or 3.0 and for HCV RNA (by using either AMPLICOR ® HCV Test, version 2.0, or HCV RNA DetectR™ PLUS by TMA, Specialty Laboratories, Santa Monica, California). Specimens positive for anti-HCV by EIA were tested with a supplemental recombinant immunoblot assay (RIBA ® , Chiron Corporation, Emeryville, California). HCV genotype was determined for all HCV RNA-positive samples (1, 2) .
Of 91 organs and tissues recovered from the donor, 44 were transplanted into 40 recipients during October 2000-July 2002. Of the remaining 47 grafts, 44 tissues were removed from distribution in July 2002, and two tissues and one organ had been discarded earlier. Of the 40 recipients, six received organs, 32 received tissues, and two received corneas. Recipients were located in 16 states and two foreign countries. All tissues had been treated with surface chemicals or antimicrobials. Bone grafts also underwent gamma irradiation.
Eight cases were identified among the 40 recipients; all cases were HCV genotype 1a. Among the six organ recipients, posttransplantation serum was available for three, and definite cases occurred in all three. Of the 32 tissue recipients, three were known to have been HCV-infected before transplantation, and test results were not available for another two (one bone and one tendon with bone recipient). Among the remaining 27 tissue recipients, five probable cases occurred: in one of two recipients of saphenous vein, in one of three recipients of tendon, and in all three recipients of tendon with bone (including the index patient). One other recipient was found to be HCV-infected after transplantation with genotype 3a. No cases occurred in recipients of skin (n = two) or irradiated bone (n = 16). Of the two cornea recipients, one was infected before transplantation. The other recipient was anti-HCV-negative; however, as of March 27, HCV RNA testing had not been performed.
MMWR April 4, 2003
Editorial Note: This report describes transmission of HCV by tissues and organs from a donor whose serum tested anti-HCV-negative at the time of death. However, stored serum tested subsequently was HCV RNA-positive. The donor was the probable source of HCV infection for at least eight recipients of organs or tissues. All cases occurred in recipients of organs or soft tissues; no infections were found among those who had received skin or irradiated bone. HCV transmission from tissue donors has been reported infrequently; the only tissue types reported previously to transmit HCV are nonirradiated bone and tendon with bone (3) (4) (5) . By contrast, transplanted organs from infected donors are known to carry a high risk for transmitting HCV (6) .
At the time of death, the donor probably was in the 8-10 week window period between infection with HCV and development of a detectable HCV-antibody response (7) . Although available data are limited, HCV transmission by organ and tissue donors during this period appears to be uncommon; only one previous report describes HCV transmission from a tissue donor in whom anti-HCV testing (using a less sensitive first-generation assay) was negative (3). The frequency of transplantation from antibody-negative, HCV RNA-positive organ and tissue donors is not known. However, among voluntary blood donors, whose characteristics probably differ from those of organ and tissue donors, approximately four per 1,000,000 blood donations are from donors who are anti-HCV-negative and HCV RNApositive (8) .
Donor screening is the primary means of preventing transmission of viral infections from organs and tissues. The Food and Drug Administration (FDA) and the Health Resources and Services Administration (HRSA) provide regulatory guidance or oversight for screening of tissue and organ donors. In addition, organ procurement organizations are required by the Centers for Medicare & Medicaid Services to ensure that appropriate donor screening tests are performed by a laboratory certified in accordance with the Clinical Laboratory Improvement Amendments of 1988. The donor screening process includes medical chart review, interview of the donor's next of kin, physical assessment, and testing of donor serum. Guidelines require that organ and tissue donors be tested for anti-HCV.
Nucleic acid testing (NAT) to detect HCV RNA among organ and tissue donors is not performed routinely and has several limitations. Organ viability declines rapidly as a function of time after donor death. Because NAT often is not immediately accessible and can require 1-2 days to complete, it might be impractical in the setting of organ transplantation. By contrast, tissues often can be stored for months to years before use, allowing ample time for NAT. However, postmortem serum frequently is the only sample available for testing from tissue donors. NAT to detect HCV RNA has not been approved by FDA for use on serum samples obtained postmortem, and the performance of available assays in this setting has not been evaluated.
Tissue processing methods (e.g., gamma irradiation) might affect the likelihood of transmission of HCV and other viruses from infected donors (3, 9) . In this investigation, no cases occurred in recipients of irradiated bone. Irradiation is not applied routinely to all tissue types because it can impair tissue structural integrity.
This investigation was initiated by a clinician who suspected allograft-associated HCV transmission and alerted the state health department. When a new case of hepatitis C is diagnosed in a recent tissue or organ recipient, health-care providers should notify local or state health departments promptly so an investigation can be initiated and, if necessary, tissues can be recalled to prevent further transmission. Centers performing transplantation should maintain adequate records of graft recipients to facilitate investigations of allograftassociated infections.
CDC, in collaboration with FDA and HRSA, will determine whether changes in organ and tissue donor screening guidelines are warranted. Assessing the performance of available NAT and anti-HCV assays in postmortem specimens would provide essential information about the period during which donor screening can be performed reliably. Although transmission from anti-HCV-negative tissue donors probably is rare, determining the frequency of transplantations from such donors and the risk for transmitting HCV to recipients will be useful for evaluating the benefits and limitations of additional prevention measures. In the United States, falls are the second leading cause of traumatic brain injury (TBI) hospitalizations overall and the leading cause of TBI hospitalizations among persons aged >65 years (1) . In 1995, TBIs resulted in an estimated $56 billion in direct and indirect costs in the United States (2). In California, during 1999, a total of 61,475 hospitalizations from falls were reported among persons aged >65 years (3). Risk factors for falling among older persons included arthritis; impairments in balance, gait, vision, and muscle strength; and the use of four or more prescription medications (2,4). As part of CDC's program of state-based TBI surveillance, California hospital discharge data were collected and analyzed to describe fall-related TBIs. This report summarizes the results of that analysis, which support previous findings that persons aged >65 years are at risk for hospitalization for a fall and that same-level falls are far more common among persons aged >65 years than falls from a higher level (e.g., a ladder, chair, or stair) (1, 2, 5) . Defining the circumstances of fall injuries and recognizing the type of fall leading to TBI hospitalizations among older persons can help health-care providers conduct risk assessment and management of falls in this population.
All nonfederal, acute care hospitals in California are required to report hospital discharges to the Office of Statewide Health Planning and Development. All first admissions with an injury diagnosis must be coded for external cause of injury (E-code); E-codes are listed in >99% of these records (5) . For this report, cases were limited to first admissions. Hospitalization records of transfers, fatal cases, and out-of-state residents were excluded by matching sex, date of birth, and a record linkage number (i.e, an encrypted social security number). Hospital discharge records were coded according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) (6) . TBI cases were defined by the most recent CDC surveillance definition, in which any of the 25 diagnoses include one of the following nature-of-injury diagnosis codes: 800.0-801.9 (fracture of the vault of the skull), 803.0-804.9 (other and unqualified skull fracture), 850.0-854.1 (intracranial injury including concussion, laceration, and hemorrhage), or 959.01 (head injury, unspecified). The primary cause of injury for falls (E880-E886, E888) was analyzed by mechanism.* Age was categorized into one younger comparison group (aged 0-64 years) and three older groups (aged 65-74 years, 75-84 years, and >85 years). Incidence rates were calculated per 100,000 population by using mid-year population estimates of California residents for each year (Epidemiology and Prevention for Injury Control, California Department of Health Services, unpublished data, 1996-1999).
During 1996-1999, a total of 29,761 fall-related TBI hospitalizations were reported; of these, 28,009 (94%) patients were discharged, and 1,752 were deceased. A total of 1,252 (71%) of fatal fall-related TBI hospitalizations were among those aged >65 years. Overall, the nonfatal fall-related TBI hospitalization rate was 21.1 per 100,000 population (95% confidence interval = 20.8-21.3) ( Table 1) . Hospitalization rates increased with age; the highest rate (223.0) was among persons aged >85 years. Compared with persons aged 0-64 years, the rate ratio of hospitalizations was 3.1 for persons aged 65-74 years, 7.6 for those aged 75-84 years, and 16.4 for those aged >85 years. Overall, males were hospitalized more frequently (59%) than females. Although 70% of hospitalizations among those aged <65 years were among males, females accounted for 56% of hospitalizations among those aged >65 years. For those aged >65 years, whites represented 78% of hospitalizations and had the highest rate (25.4) among all racial/ethnic populations.
In 9,364 (33%) hospitalizations, the type of fall was coded "other and unspecified" (E888). Among the 18,645 specified falls, the pattern differed by age group (Table 2) . Among persons aged 0-64 years, 75% of falls were from at least one level. Among persons aged >65 years, 60% of falls were on the same level. For the three older population groups, the * E880 (fall on or from stairs or steps); E881 (fall on or from ladders or scaffolding); E882 (fall from or out of structure); E883 (fall into opening in surface); E884 (other fall from one level to another); E885 (fall on same level from slipping, tripping, or stumbling); E886 (fall on same level from collision, pushing, or shoving, by or with other person); and E888 (other and unspecified fall). proportion of specified falls on the same level also varied: 52% among persons aged 65-74 years, 61% among those aged 75-84 years, and 66% among those aged >85 years. By race/ethnicity for all age groups, the proportion of specified falls on the same level was 40% for whites, 31% for blacks, 23% † for Hispanics, 36% for Asians/Pacific Islanders, and 33% for American Indians/Alaska Natives. Among persons aged 0-64 years, 13,792 (86%) were discharged with only self-care or unskilled care provided. The remainder were sent to another facility or discharged with inhome health services or outpatient rehabilitation. Among persons aged >65 years, the number discharged was 4,927 (41%). The proportion of persons discharged home decreased † A total of 97% of Hispanic fall injury patients of known race are classified as white.
with increasing age. For those aged >85 years, the number discharged was 1,071 (30%) compared with 2,083 (41%) for those aged 75-84 years and 1,773 (54%) for those aged 65-74 years. Editorial Note: In California, fall-related TBIs have a substantial impact on the health-care delivery system. Among those aged >85 years, three out of five hospitalizations resulted in a discharge to a residential facility with skilled nursing or to an in-home health service with outpatient rehabilitation services. Among older persons, an estimated annual average of 3,000 nonfatal falls results in hospitalizations for
TBI at an estimated cost of $50 million § . Studying the nature of these injuries and demographic risk factors might inform intervention strategies. However, few reports have been published regarding hospitalizations for fall-related TBIs (1,2). The overall rate of hospitalized TBI falls observed in California (21.1) is similar to the combined incidence rate of hospitalized TBI falls (23.3) reported by Colorado, Missouri, Oklahoma, and Utah (1). Although the number of patients who returned to their pre-injury level of functioning is unknown, TBI often results in lifelong neurologic, psychological, and cognitive conditions requiring rehabilitation therapy and other treatment (7) . This study indicates that for older adults, these injuries often result in death or impairment.
Rates of fall-related TBI are historically higher in males (8) . In this study, rates observed in males also exceeded those of females in every age group, compared with all fall injury rates (i.e., those including other injuries in addition to TBI), which usually are higher for females (5) . The reasons for this difference are unclear.
Adults aged >65 years have elevated TBI hospitalization rates (1). Older persons are at increased risk for fallrelated TBI hospitalizations for at least three reasons. First, older persons are more likely to have chronic diseases and to use more medications whose adverse effects can lead to falls (4,9,10). Certain medications (e.g., sedatives, benzodiazepines, anticonvulsants, and antihypertensives) might cause dizziness, drowsiness, and postural hypotension (4, 10) . Second, even without medication effects, older adults might have impaired balance, slower reaction times, and decreased muscle strength, all of which can lead to more frequent falls. Finally, older adults who fall often sustain more severe head injuries than their younger counterparts (5). Falls are a major cause of intracranial lesion among older persons because of their greater susceptibility to acute subdural hematoma (10) .
The findings in this report are subject to at least four limitations. First, because TBI cases were identified when any of the 25 diagnoses included a TBI diagnosis code, TBI might not be the primary reason for hospital admission or even the most serious problem. In this report, 21,593 (77%) of cases had TBI as the primary diagnosis. Second, the data source did not include intrinsic risk factors such as medications, comorbidities, or physical condition. Third, one third of TBI patients did not specify the type of fall, making it difficult to characterize what type of falls cause TBI. Finally, hospitalization records were not reviewed to validate the E-codes for fall-related TBI. § Average charges (including all inpatient charges except physician fees) for a fall hospitalization in California in 1999 are $17,086 (4).
Falls are a major cause of TBI in older persons. As the population of older persons in the United States continues to grow, the number of TBIs also is likely to grow. Recent clinical trials have identified fall prevention strategies that are effective in reducing the number of falls (e.g., balance and gait training, strength exercise programs, discontinuation of psychotropic medication, and reduction in home hazards after hospitalization) (4) . Integration of these strategies into public health programs might reduce TBI-related morbidity and health-care costs.
Update: Adverse Events Following Smallpox VaccinationUnited States, 2003
During January 24-March 28, 2003, smallpox vaccine was administered to 29,584 civilian health-care and public health workers in 54 jurisdictions as part of an effort to prepare the United States for a terrorist attack using smallpox virus. This report summarizes data on ten cases of cardiac adverse events reported among civilian vaccinees since the beginning of the smallpox vaccination program, including three new cardiac adverse events reported to CDC from the Vaccine Adverse Event Reporting System (VAERS) during March 24-30. Fourteen cases of myocarditis and one fatal myocardial infarction have been reported among military personnel. This report summarizes data on the three new cases of cardiac adverse events, updates data on seven previously reported cases among civilian vaccinees (Table 1) (1), summarizes selected cases of cardiac adverse events among military vaccinees, and updates information on all adverse events reported in the civilian vaccination program as of March 30.
CDC, the Food and Drug Administration, and state health departments are conducting surveillance for vaccineassociated adverse events among civilian vaccinees; the Department of Defense (DoD) is conducting surveillance for vaccine-associated adverse events among military vaccinees. In the first stage of the civilian program, active surveillance is being conducted for any adverse events after vaccination that require medical care. In the military vaccination program, military personnel receive medical care primarily in a network of linked clinics, which report adverse events to medical headquarters and VAERS.
Civilian Case Reports
The three new cases of cardiac adverse events among civilians during March 24-30 include two cases of myopericarditis and one case of myocardial infarction (Table 1) . Case 1. A man aged 56 years with a history of mild hypertension and hypertriglyceridemia was revaccinated on March 4. On March 16, he had onset of influenza-like illness (ILI), chest discomfort while lying flat, and pleuritic pain during inspiration; a clinical examination revealed tachycardia. During the next 7 days, he had chest pain, dyspnea on exertion, fever, chills, pallor, and left knee pain. All symptoms and signs had resolved 17 days after vaccination. On day 23 post vaccination, an electrocardiogram (ECG) indicated low R waves in the anterior leads, and borderline first-degree AV block (PR interval: 0.21 msec). Echocardiogram revealed widening of the pericardial space with minimal fluid collection, a normal ejection fraction, and normal ventricular wall function. Chest radiograph demonstrated left basilar atelectasis. The patient had normal troponin I, creatine kinase myocardial band (CK-MB), C-reactive protein levels, and a normal erythrocyte sedimentation rate. These findings are consistent with mild myopericarditis. The patient recovered; a followup exercise cardiac perfusion scan was normal. Case 2. A woman aged 32 years with no history of cardiac disease or major risk factors for coronary artery disease was vaccinated for the first time on January 31. On February 16, she had fever, crushing-type chest pain, and shortness of breath, which prompted a visit to the emergency department (ED). An ECG indicated nonspecific ST-T wave changes; cardiac enzymes were normal. A repeat ECG several days later was normal. After 5-6 days, her symptoms resolved completely, and she was able to resume normal activities. Six weeks after vaccination, a nuclear stress test was normal. Her clinical course and ECG findings were consistent with myopericarditis.
Case 3. An active man aged 64 years with a history of dyspnea on exertion and productive cough for 3 months and eight previous smallpox vaccinations was revaccinated on March 21. On March 23, he sought medical care for chest "fullness" and dizziness. Blood tests indicated elevated troponin I and CK-MB levels. ECG demonstrated inferior ST segment depression and T wave inversion. Echocardiography indicated moderate inferior wall hypokenesis with a normal ejection fraction. Coronary arteriography showed three-vessel atherosclerotic disease with development of some collateral circulation. The patient underwent cardiac catheterization with ballon atherotomy, and two coronary artery stents were placed. The clinical course and laboratory findings are consistent with acute myocardial infarction in a patient with chronic coronary artery disease. He returned to work on March 31.
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Update on Previous Civilian Cardiac Adverse Events
On March 23, a woman aged 55 years with a history of hypertension, hypercholesterolemia, and smoking died 5 days after smallpox vaccination (1) . Autopsy showed extensive atherosclerotic disease, with right coronary artery thrombosis and lateral wall softening. Preliminary testing, including realtime polymerase chain reaction (PCR) and immunohistochemistry, showed evidence of vaccinia virus only at the vaccination site; limited analyses of other tissues, including heart and other visceral tissue, were negative for vaccinia virus by real-time PCR and immunohistochemistry.
On March 26, a woman aged 57 years with a history of smoking, hypertension, transient ischemic attack, and carotid endarterectomy died 22 days after smallpox vaccination (1). Autopsy showed extensive atherosclerosis of the coronary arteries, and a large healing infarct involving the posterior wall of the left ventricle and intraventricular septum. Histopathologic evaluation revealed no evidence of myocarditis or pericarditis. Preliminary analysis using real-time PCR tests showed evidence of vaccinia virus DNA at the vaccination site but not in affected myocardium and other viscera.
Military Case Reports
During March 25-31, four cases of myocarditis and/or pericarditis were identified, totaling 14 cases among approximately 250,000 personnel who received smallpox vaccination for the first time. No cases of myocarditis and/or pericarditis were identified among approximately 115,000 service members who were revaccinated. Among the approximately 365,000 vaccinated military service members, one death has been reported.
The 14 patients with myocarditis and/or pericarditis ranged in age from 21 to 33 years. Severity ranged from mild (no ECG or echocardiogram changes) to severe (congestive heart failure), with onset 7 to 19 days after vaccination. All military patients were hospitalized, and all survived. As of April 2, the patient with the most severe case has been hospitalized for 6 days. All other hospitalized patients have been discharged; they have either returned to duty or are on short-term convalescent leave. Following are two cases that represent the spectrum of clinical presentations of myopericarditis and a report of a fatal case of myocardial infarction. Case 1. On March 18, a man aged 22 years sought medical care at a military health clinic for chest pain 12 days after primary smallpox vaccination. He was treated with nonsteroidal anti-inflammatory agents for presumed costochondritis. When laboratory tests revealed elevated cardiac enzymes levels, he was referred to a university hospital emergency department (ED) for further evaluation. Cardiac enzymes levels remained elevated, but an ECG, echocardiogram, and cardiac stress test were normal. Myopericarditis was diagnosed, and he was released that day in good condition.
Case 2. A man aged 29 years had ILI symptoms during the same week of primary smallpox vaccination. At the time of smallpox vaccination on March 8, he also received five other inactivated vaccines; 19 days after vaccination, he sought treatment at an ED for dyspnea while lying flat. On March 28, he was hospitalized and had myopericarditis diagnosed based on ECG findings and elevated troponin I and CK-MB. The next day, he had pulmonary edema with a pulmonary artery wedge pressure of 38 mmHg that responded well to several doses of intravenous diuretics. Serial echocardiograms showed ejection fractions as low as 25% that subsequently improved to 45% (normal: >55%). Endomyocardial biopsy revealed active myocarditis with a mixed infiltrate of lymphocytes and eosinophils and evidence of eosinophilic degranulation in proximity to myocyte necrosis. PCR testing of myocardial tissue was negative for vaccinia virus DNA, varicella-zoster virus DNA, and herpes simplex virus DNA; reverse transcriptase PCR was negative for enterovirus RNA. As of April 2, he remained hospitalized but was stable and improving.
Case 3. On March 25, an Army National Guardsman aged 55 years with a history of smoking and treatment for hyperlipidemia was found unresponsive in a vehicle 5 days after receiving smallpox vaccine and two other inactivated vaccines. He was resuscitated but died the next day. Autopsy showed acute thrombosis of the right anterior descending coronary artery, three-vessel coronary artery disease with 75%-80% occlusion, left ventricular hypertrophy, and cardiomegaly. Histopathology of left ventricular myocardium revealed no evidence of myocarditis or pericarditis. Virologic testing of myocardium is pending. The cause of death was acute myocardial infarction.
Update on Adverse Events in the Civilian Vaccination Program
As of March 30, no cases of several potentially lifethreatening adverse events associated historically with smallpox vaccination (i.e., progressive vaccinia, eczema vaccinatum, post-vaccinial encephalitis, or encephalomyelitis) have been reported among civilians. In addition, no cases of vaccinia transmission from civilians have been reported. This includes no transmission from 18,344 members of health-care teams, 6,655 of whom have been followed for >1 month.
During March 11-30, six cases of generalized vaccinia, 14 cases of inadvertent inoculation (nonocular), and four cases of myopericarditis were reported (Table 2 ). During the same illness, or death; these events are associated temporally with smallpox vaccination but are not necessarily associated causally with vaccination. § Includes myocardial infarction (n = four), angina (n = two), headache (n = two), pancreatic cancer (n = one), urinary tract infection (n = one), herpes zoster virus infection (n = one), and facial paralysis and paresthesias (n = one). ¶ Include expected self-limited responses to smallpox vaccination (e.g., fatigue, headache, pruritis, local reaction at vaccination site, regional lymphadenopathy, lymphangitis, fever, myalgia and chills, and nausea); additional events are associated temporally with smallpox vaccination but are not necessarily associated causally with vaccination. period, 12 other serious adverse events were reported. Of these, four were myocardial infarctions, and two were cases of angina (Table 3 ). The remaining six other new serious adverse events had hospital discharge diagnoses of pancreatic cancer, urinary tract infection, herpes zoster virus infection, headache, and facial paralysis with paresthesias (Table 3) . Among the 192 vaccinees with reported other nonserious adverse events during January 24-March 30 (Table 3) , the most common signs and symptoms were fever (n = 42), rash (n = 39), headache (n = 34), and pruritus (n = 32). All of these commonly reported events are consistent with mild expected reactions after receipt of smallpox vaccine. Some vaccinees reported multiple signs and symptoms. During March 11-30, no vaccinia immune globulin was released for civilian vaccinees (Table 4) . Surveillance for adverse events during the civilian and military smallpox vaccination programs is ongoing; regular surveillance reports will be published in MMWR. Editorial Note: New reports of myopericarditis following smallpox vaccination are consistent with previous reports describing a potential causal association between vaccination and myopericarditis (1) . One new case of myocardial infarction among civilian vaccinees and one death from myocardial infarction among military vaccinees have been reported, but any association between smallpox vaccine and ischemic heart disease remains unclear.
Myopericarditis is often asymptomatic or mild, but can be severe. Symptomatic patients report chest pain, fatigue, fever, palpitations, and dyspnea on exertion. The patient with myopericarditis and congestive heart failure reported by DoD illustrates the potential severity of the condition, which can lead to severe cardiac dysfunction or dysrhythmia. In addition, rare fatal cases of myocarditis after smallpox vaccination have been reported in Europe and Australia (2, 3) . Evaluation and follow-up guidelines are being developed by CDC to assist health-care providers in managing vaccinees with cardiac adverse events.
Preliminary autopsy findings for the three patients with myocardial infarction who died showed no evidence of disseminated vaccinia infection or myopericarditis. Although virologic testing of myocardial tissue is pending for one patient and is limited for the other two, these findings suggest the ischemic events in these patients did not result from vaccinia-associated myocarditis. The number of reported deaths from cardiac disease among civilians and military personnel is consistent with expected background rates (1). However, it is not known whether smallpox vaccination could contribute to these events through another mechanism.
On the basis of the civilian and military cases, and guidance from the Advisory Committee on Immunization Practices (4) and an independent group of cardiology consultants, CDC revised its recommendations for screening and exclusion of potential smallpox vaccine recipients. Persons should be excluded from the pre-event smallpox vaccination program if they have had heart disease or any type of ischemic cardiovascular disease diagnosed, with or without symptoms (e.g., previous myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack, or other heart conditions under the care of a doctor). Persons also should be excluded if they have three or more risk factors: hypertension, diabetes, hypercholesterolemia, smoking, or an immediate family member who had onset of a heart condition before age 50. To date, five of the six vaccinated civilians with cardiac adverse events indicative of ischemic heart disease met these exclusion criteria.
Notice to Readers
Supplemental Recommendations on Adverse Events Following Smallpox Vaccine in the Pre-Event Vaccination Program: Recommendations of the Advisory Committee on Immunization Practices
The Advisory Committee on Immunization Practices (ACIP) has issued recommendations previously for use of smallpox vaccine (1) and supplemental recommendations for use of smallpox vaccine in the pre-event civilian vaccination program (2). On March 28, 2003, CDC reported cases of cardiac adverse events among persons vaccinated recently with smallpox vaccine (3) . In response to these reports, ACIP held an emergency meeting on March 28 to make recommendations to CDC about medical screening of potential vaccinees and follow-up of persons with cardiovascular risk factors after vaccination. These recommendations supplement those previously issued by ACIP (1,2).
As of March 28*, a total of 10 cases of myopericarditis had been reported among approximately 240,000 primary vaccinees in the military vaccination program, and two such cases (one of myocarditis and one of pericarditis) had been reported among civilian vaccinees (3) . No cases of myopericarditis had been reported among approximately 110,000 military revaccinees. Patients whose cases were reported to the U.S. Department of Defense had onset 7-12 days after vaccination and had illness diagnosed based on clinical features, laboratory studies, and electrocardiographic or echocardiographic features. Compared with the rate reported in an unvaccinated military population during 1998-2000, the rate of myopericarditis is substantially elevated (U.S. Department of Defense, unpublished data, 2001).
As of March 28, CDC had received reports of five civilian patients with cardiac ischemic events after smallpox vaccination, including three patients with myocardial infarctions and two patients with angina. The five patients with ischemic events ranged in age from 43 to 60 years, and four of the five were aged >54 years; four were women. 
cdc.gov/mmwr
George Santayana underlying cardiovascular risk factors. One had known cardiovascular disease, and two others had histories of chest pain (not clearly identified as cardiac in origin on the basis of available information). Two patients died, both from myocardial infarctions with out-of-hospital cardiac arrests. Onset of cardiac symptoms occurred 4, 4, 5, 9, and 17 days after vaccination in the five patients; the patient who experienced a cardiac arrest 17 days after vaccination had symptoms of nausea, dizziness, shortness of breath, fever, and productive cough 5 days after vaccination. Two patients were revaccinees, but the previous vaccination status of the other patients is unknown; all were children at a time when the majority of children in the United States received smallpox vaccine. The two deaths due to cardiac disease among civilian vaccinees are similar to the numbers expected among persons in these age groups in the general population in the absence of vaccination (3). The military reported an additional case of a myocardial infarction and out-of-hospital cardiac arrest in a man aged 55 years with multiple cardiac risk factors; the cardiac arrest occurred 5 days after vaccination (U.S. Department of Defense, personal communication, 2003) .
These data are consistent with a causal relation between myocarditis/pericarditis and smallpox vaccination, but no causal association between the ischemic cardiac events and smallpox vaccination has been identified. In response to these reports, CDC issued a health advisory on March 26, recommending as a precautionary measure that persons with known cardiac disease not be vaccinated as response team members in the pre-event smallpox vaccination program at this time (4) . Persons receiving smallpox vaccine should be informed that myopericarditis is a potential complication of smallpox vaccination and that they should seek medical attention if they develop chest pain, shortness of breath, or other symptoms of cardiac disease within 2 weeks after vaccination.
ACIP recommends that persons be excluded from the preevent smallpox vaccination program who have known underlying heart disease, with or without symptoms, or who have three or more known major cardiac risk factors (i.e., hypertension, diabetes, hypercholesterolemia, heart disease at age 50 years in a first-degree relative, and smoking). ACIP supported including these risk factors in prevaccination education materials so that potential vaccinees can evaluate their risk status, if they have concerns, with their personal physician before reporting for vaccination; at the vaccination clinic, verbal screening for known risk factors is recommended. In response to these recommendations, prevaccination screening forms and other materials have been revised; these materials have been provided to state health departments and are available at http://www.bt.cdc.gov/agent/smallpox. ACIP did not recommend special medical follow-up for persons with cardiovascular risk factors who have been vaccinated. Persons with risk factors or known atherosclerotic coronary artery disease should be cared for by their physicians in accordance with standard guidelines for treatment and control of these conditions, such as those issued by the National Cholesterol Education Program Expert Panel and other expert groups (5). .  23  23  ----476  547  5,414  5,987  Alaska  ------16  19  87  159  Hawaii  -3  ----22  29  230 134 
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